{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:52Z","timestamp":1790138692260,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["KiKa-236"],"award-info":[{"award-number":["KiKa-236"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF-11863"],"award-info":[{"award-number":["KWF-11863"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-024-06916-w","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T21:01:22Z","timestamp":1727989282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-6762","authenticated-orcid":false,"given":"Tamara C. A. I.","family":"Verbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten S.","family":"Vrenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T. C. J. M.","family":"Arentsen-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Garrido","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-9353","authenticated-orcid":false,"given":"Marieke","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"van Tellingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"6916_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer, C. et al. The MLL recombinome of acute leukemias in 2017. Leukemia 32, 273\u2013284 (2018).","journal-title":"Leukemia"},{"key":"6916_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.leu.2404578","volume":"21","author":"MW Jansen","year":"2007","unstructured":"Jansen, M. W. et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 21, 633\u2013641 (2007).","journal-title":"Leukemia"},{"key":"6916_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters, R. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370, 240\u2013250 (2007).","journal-title":"Lancet"},{"key":"6916_CR4","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.19.00261","volume":"37","author":"R Pieters","year":"2019","unstructured":"Pieters, R. et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J. Clin. Oncol. 37, 2246\u20132256 (2019).","journal-title":"J. Clin. Oncol."},{"key":"6916_CR5","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis, I. M. et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N. Engl. J. Med 388, 1572\u20131581 (2023).","journal-title":"N. Engl. J. Med"},{"key":"6916_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.tips.2016.05.005","volume":"37","author":"K Cermakova","year":"2016","unstructured":"Cermakova, K., Weydert, C., Christ, F., De Rijck, J. & Debyser, Z. Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia. Trends Pharm. Sci. 37, 660\u2013671 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"6916_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1101\/gad.2015411","volume":"25","author":"E Smith","year":"2011","unstructured":"Smith, E., Lin, C. & Shilatifard, A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25, 661\u2013672 (2011).","journal-title":"Genes Dev."},{"key":"6916_CR8","doi-asserted-by":"publisher","first-page":"e955330","DOI":"10.1080\/23723548.2014.955330","volume":"1","author":"E Ballabio","year":"2014","unstructured":"Ballabio, E. & Milne, T. A. Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol. Cell Oncol. 1, e955330 (2014).","journal-title":"Mol. Cell Oncol."},{"key":"6916_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nrm3931","volume":"16","author":"E Verdin","year":"2015","unstructured":"Verdin, E. & Ott, M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. 16, 258\u2013264 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"6916_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bjh.15436","volume":"182","author":"N Vega-Garc\u00eda","year":"2018","unstructured":"Vega-Garc\u00eda, N. et al. Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases. Br. J. Haematol. 182, 542\u2013553 (2018).","journal-title":"Br. J. Haematol."},{"key":"6916_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673\u2013691 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"6916_CR12","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen, R., Harihar, D. & Chatterji, B. P. Recent histone deacetylase inhibitors in cancer therapy. Cancer 129, 3372\u20133380 (2023).","journal-title":"Cancer"},{"key":"6916_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175216","volume":"931","author":"R Hai","year":"2022","unstructured":"Hai, R. et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur. J. Pharm. 931, 175216 (2022).","journal-title":"Eur. J. Pharm."},{"key":"6916_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/leu.2017.216","volume":"32","author":"P Garrido Castro","year":"2018","unstructured":"Garrido Castro, P. et al. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20\/RNF40\/WAC-H2B ubiquitination axis. Leukemia 32, 323\u2013331 (2018).","journal-title":"Leukemia"},{"key":"6916_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/10428194.2017.1372575","volume":"59","author":"M Offidani","year":"2018","unstructured":"Offidani, M. et al. Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed\/refractory multiple myeloma. Leuk. Lymphoma 59, 1271\u20131273 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"6916_CR16","first-page":"1","volume":"6","author":"B Poligone","year":"2011","unstructured":"Poligone, B., Lin, J. & Chung, C. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid. 6, 1\u201312 (2011).","journal-title":"Core Evid."},{"key":"6916_CR17","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","volume":"12","author":"MH Shah","year":"2006","unstructured":"Shah, M. H. et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res 12, 3997\u20134003 (2006).","journal-title":"Clin. Cancer Res"},{"key":"6916_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","volume":"114","author":"E Ceccacci","year":"2016","unstructured":"Ceccacci, E. & Minucci, S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br. J. Cancer 114, 605\u2013611 (2016).","journal-title":"Br. J. Cancer"},{"key":"6916_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1074\/mcp.O114.046565","volume":"14","author":"RA Mathias","year":"2015","unstructured":"Mathias, R. A., Guise, A. J. & Cristea, I. M. Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease. Mol. Cell Proteom. 14, 456\u2013470 (2015).","journal-title":"Mol. Cell Proteom."},{"key":"6916_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet 10, 32\u201342 (2009).","journal-title":"Nat. Rev. Genet"},{"key":"6916_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tim.2013.02.005","volume":"21","author":"K Shirakawa","year":"2013","unstructured":"Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21, 277\u2013285 (2013).","journal-title":"Trends Microbiol"},{"key":"6916_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","volume":"150","author":"Moreno DA","year":"2010","unstructured":"Moreno DA et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 150, 665\u2013673 (2010).","journal-title":"Br. J. Haematol."},{"key":"6916_CR23","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-14-1290","volume":"21","author":"MC Stubbs","year":"2015","unstructured":"Stubbs, M. C. et al. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin. Cancer Res 21, 2348\u20132358 (2015).","journal-title":"Clin. Cancer Res"},{"key":"6916_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","volume":"96","author":"V Wachholz","year":"2022","unstructured":"Wachholz, V. et al. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch. Toxicol. 96, 177\u2013193 (2022).","journal-title":"Arch. Toxicol."},{"key":"6916_CR25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fcell.2020.00844","volume":"8","author":"M Spreafico","year":"2020","unstructured":"Spreafico, M. et al. HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia. Front Cell Dev. Biol. 8, 844 (2020).","journal-title":"Front Cell Dev. Biol."},{"key":"6916_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2014.39","volume":"3","author":"K Ahmad","year":"2014","unstructured":"Ahmad, K. et al. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis 3, e127 (2014).","journal-title":"Oncogenesis"},{"key":"6916_CR27","doi-asserted-by":"publisher","first-page":"25784","DOI":"10.18632\/oncotarget.4703","volume":"6","author":"K Ahmad","year":"2015","unstructured":"Ahmad, K. et al. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3. Oncotarget 6, 25784\u201325800 (2015).","journal-title":"Oncotarget"},{"key":"6916_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/leu.2011.278","volume":"26","author":"DJ Stumpel","year":"2012","unstructured":"Stumpel, D. J. et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26, 682\u2013692 (2012).","journal-title":"Leukemia"},{"key":"6916_CR29","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41375-020-01097-x","volume":"35","author":"O de Barrios","year":"2021","unstructured":"de Barrios, O. et al. HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia. Leukemia 35, 2086\u20132091 (2021).","journal-title":"Leukemia"},{"key":"6916_CR30","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41388-020-01408-7","volume":"39","author":"M Ge","year":"2020","unstructured":"Ge, M. et al. Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene 39, 5888\u20135901 (2020).","journal-title":"Oncogene"},{"key":"6916_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1677\/JME-10-0043","volume":"45","author":"A Nebbioso","year":"2010","unstructured":"Nebbioso, A. et al. HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J. Mol. Endocrinol. 45, 219\u2013228 (2010).","journal-title":"J. Mol. Endocrinol."},{"key":"6916_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051028","volume":"21","author":"A Nebbioso","year":"2020","unstructured":"Nebbioso, A. et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 21, e51028 (2020).","journal-title":"EMBO Rep."},{"key":"6916_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.848938","volume":"9","author":"X He","year":"2022","unstructured":"He, X. et al. Selective Inhibition of Histone Deacetylase Class IIa With MC1568 Ameliorates Podocyte Injury. Front. Med. (Lausanne) 9, 848938 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"6916_CR34","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1096\/fj.201801067RR","volume":"33","author":"C Xiong","year":"2019","unstructured":"Xiong, C. et al. Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis. FASEB J. 33, 8249\u20138262 (2019).","journal-title":"FASEB J."},{"key":"6916_CR35","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","volume":"23","author":"QC Ryan","year":"2005","unstructured":"Ryan, Q. C. et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23, 3912\u20133922 (2005).","journal-title":"J. Clin. Oncol."},{"key":"6916_CR36","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/jcmm.14188","volume":"23","author":"SY Choi","year":"2019","unstructured":"Choi, S. Y. et al. Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension. J. Cell Mol. Med 23, 2801\u20132812 (2019).","journal-title":"J. Cell Mol. Med"},{"key":"6916_CR37","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1093\/hmg\/ddw231","volume":"25","author":"S Trazzi","year":"2016","unstructured":"Trazzi, S. et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum. Mol. Genet 25, 3887\u20133907 (2016).","journal-title":"Hum. Mol. Genet"},{"key":"6916_CR38","doi-asserted-by":"publisher","unstructured":"Spaety ME, et al. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73\/BIK Pathway. Cancers (Basel). 11 https:\/\/doi.org\/10.3390\/cancers11111747 (2019).","DOI":"10.3390\/cancers11111747"},{"key":"6916_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fcell.2020.00400","volume":"8","author":"B Tu","year":"2020","unstructured":"Tu, B., Zhang, M., Liu, T. & Huang, Y. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Front Cell Dev. Biol. 8, 400 (2020).","journal-title":"Front Cell Dev. Biol."},{"key":"6916_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202000039","volume":"20","author":"H Lindemann","year":"2020","unstructured":"Lindemann, H. et al. Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery. Macromol. Biosci. 20, e2000039 (2020).","journal-title":"Macromol. Biosci."},{"key":"6916_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","volume":"22","author":"WGB Singleton","year":"2018","unstructured":"Singleton, W. G. B. et al. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery. J. Neurosurg. Pediatr. 22, 288\u2013296 (2018).","journal-title":"J. Neurosurg. Pediatr."},{"key":"6916_CR42","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/0008-5472.CAN-18-1421","volume":"79","author":"D Wang","year":"2019","unstructured":"Wang, D. et al. Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells. Cancer Res 79, 1769\u20131783 (2019).","journal-title":"Cancer Res"},{"key":"6916_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117213","volume":"83","author":"L Du","year":"2023","unstructured":"Du, L. et al. Development of sulfonium tethered peptides conjugated with HDAC inhibitor to improve selective toxicity for cancer cells. Bioorg. Med Chem. 83, 117213 (2023).","journal-title":"Bioorg. Med Chem."},{"key":"6916_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108893","volume":"204","author":"B Rein","year":"2022","unstructured":"Rein, B., Conrow-Graham, M., Frazier, A., Cao, Q. & Yan, Z. Inhibition of histone deacetylase 5 ameliorates abnormalities in 16p11.2 duplication mouse model. Neuropharmacology 204, 108893 (2022).","journal-title":"Neuropharmacology"},{"key":"6916_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.14411","volume":"176","author":"L Frishman-Levy","year":"2017","unstructured":"Frishman-Levy, L. & Izraeli, S. Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. Br. J. Haematol. 176, 157\u2013167 (2017).","journal-title":"Br. J. Haematol."},{"key":"6916_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-020-09848-z","volume":"39","author":"L Lenk","year":"2020","unstructured":"Lenk, L., Alsadeq, A. & Schewe, D. M. Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metast. Rev. 39, 173\u2013187 (2020).","journal-title":"Cancer Metast. Rev."},{"key":"6916_CR47","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","volume":"106","author":"RW Stam","year":"2005","unstructured":"Stam, R. W. et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106, 2484\u20132490 (2005).","journal-title":"Blood"},{"key":"6916_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1294339","volume":"6","author":"SM Johnson","year":"2017","unstructured":"Johnson, S. M. et al. Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton. J. Extracell. Vesicles 6, 1294339 (2017).","journal-title":"J. Extracell. Vesicles"},{"key":"6916_CR49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/leu.2010.155","volume":"24","author":"A Gessner","year":"2010","unstructured":"Gessner, A. et al. Leukemic fusion genes MLL\/AF4 and AML1\/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 24, 1751\u20131759 (2010).","journal-title":"Leukemia"},{"key":"6916_CR50","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"6916_CR51","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood.V76.11.2327.2327","volume":"76","author":"R Pieters","year":"1990","unstructured":"Pieters, R. et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76, 2327\u20132336 (1990).","journal-title":"Blood"},{"key":"6916_CR52","doi-asserted-by":"publisher","first-page":"e0237096","DOI":"10.1371\/journal.pone.0237096","volume":"15","author":"R van Eenige","year":"2020","unstructured":"van Eenige, R. et al. RandoMice, a novel, user-friendly randomization tool in animal research. PLoS One 15, e0237096 (2020).","journal-title":"PLoS One"},{"key":"6916_CR53","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","volume":"36","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics 36, 2645 (2020).","journal-title":"Bioinformatics"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06916-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T22:02:20Z","timestamp":1727992940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06916-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6916"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06916-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments, if not stated differently, were carried out according to Dutch legislation and approved by the Animal Ethics Committee (Approval Number: AVD3990020173066 & AVD39900202216167) at the Princess M\u00e1xima Center, Utrecht, The Netherlands. The pharmacokinetics study for LMK-235 was approved by the Animal Ethics Committee (Approval Number: AVD301002016407) at the Netherlands Cancer Institute, Amsterdam, The Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"1257"}}